|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date11 Mar 2005 |
Target- |
Mechanismllysin based antibiotics |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
A randomised, double-blind, placebo-controlled, single ascending dose, Phase I study to evaluate the safety, tolerability, and pharmacokinetics of PG110 (anti-NGF monoclonal antibody) in patients with pain attributed to osteoarthritis of the knee - Safety and tolerability of PG110 in patients with knee osteoarthritis pain
100 Clinical Results associated with Abbott
0 Patents (Medical) associated with Abbott
100 Deals associated with Abbott
100 Translational Medicine associated with Abbott